Topical rapamycin for acanthosis nigricans in the Fitzpatrick IV/V adolescent population. (Record no. 5865)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01866nam a22003257a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201229s20202020 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0736-8046 |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1111/pde.14404 [doi] |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| PMID | 33099783 |
| 245 ## - TITLE STATEMENT | |
| Title | Topical rapamycin for acanthosis nigricans in the Fitzpatrick IV/V adolescent population. |
| 251 ## - Source | |
| Source | Pediatric Dermatology. 2020 Oct 24 |
| 252 ## - Abbreviated Source | |
| Abbreviated source | Pediatr Dermatol. 2020 Oct 24 |
| 253 ## - Journal Name | |
| Journal name | Pediatric dermatology |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Year | 2020 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Manufacturer | FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Publication status | aheadofprint |
| 266 ## - Date added to catalog | |
| Date added to catalog | 2020-12-29 |
| 520 ## - SUMMARY, ETC. | |
| Abstract | Dermatologically, FGFR3 mutations can lead to acanthosis nigricans (AN), epidermal nevi, and seborrheic keratosis. A recent case report found that topical rapamycin (sirolimus) can improve FGFR3-induced epidermal nevi with AN features in children, specifically with Fitzpatrick skin type (FST) I/II, and we would like to expand these findings to skin plaques with extensive AN-like features in the FST IV/V adolescent population. An 18-year-old female with FST IV/V and FGFR3-induced hypochondroplasia presented to our clinic with extensive AN-like plaques. Significant improvement with lightening and thinning of the plaques was observed after applying 1% topical rapamycin cream twice daily. Topical rapamycin should be considered as a treatment option for AN, particularly in FST IV/V adolescents with FGFR3-induced AN. Copyright (c) 2020 Wiley Periodicals LLC. |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
| Institution | MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION | |
| Department | Dermatology |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | DeKlotz, Cynthia |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | Todd, Sarah P |
| 790 ## - Authors | |
| All authors | Coerdt KM, DeKlotz CMC, Todd SP |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| DOI | <a href="https://dx.doi.org/10.1111/pde.14404">https://dx.doi.org/10.1111/pde.14404</a> |
| Public note | https://dx.doi.org/10.1111/pde.14404 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
| Item type description | Article |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedStar Authors Catalog | MedStar Authors Catalog | 12/29/2020 | 33099783 | 33099783 | 12/29/2020 | 12/29/2020 | Journal Article |